Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...

This important study provides solid evidence that glucosylceramide synthase (GlcT), a rate-limiting enzyme for glycosphingolipid (GSL) production, plays a role in the differentiation of intestinal ...

With the theoretical part extended, this paper would be of interest to cell biologists and biophysicists working on asymmetric partitioning during cell division. Asymmetric partition of fate ...

Ratings for Lineage Cell Therapeutics LCTX were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology ...

THE CANADIAN PRESS/Chad Hipolito B.C. Conservative Party Leader John Rustad explained away some of the arguments within his party at their convention in Nanaimo last weekend. “If everybody was ...

Aberrant B-cell function, which could arise from various underlying causes, is central to the pathogenesis of diverse autoimmune rheumatic diseases. B cells remain the only cell type to be ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious ...

With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease ...

We've identified the following companies as similar to Lineage Cell Therapeutics Inc because they operate in a related industry or sector. We also considered size, growth, and various financial ...

Lineage, Inc. emphasized its strong operational performance, backed by innovation and strategic capital deployment, while navigating a challenging market environment. The LinOS system and state-of ...